tbuckley/cabot-search huggingface dataset:
A Young Woman With Viral Myocarditis
Authors: Roopa Rao, Asad J. Torabi, Kashif Saleem
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A framework for fibrolamellar carcinoma research and clinical trials
Authors: Timothy A. Dinh, Alan F. Utria, Kevin C. Barry, Rosanna Ma, Ghassan K. Abou-Alfa, John D. Gordan, Elizabeth M. Jaffee, John D. Scott, Jessica Zucman-Rossi, Allison F. O’Neill, Mark E. Furth, Praveen Sethupathy
Journal: Nature Reviews Gastroenterology & Hepatology (2022)
Validation of a 22-gene epithelial-mesenchymal transition (EMT) prognostic signature in clear cell renal cell carcinoma.
Authors: Brittney Cotta, Srinivas Nallandhighal, Judith Stangl-Kremser, Trinh Pham, Jeffrey J. Tosoian, Kathryn Marchetti, Joel Berends, Mahir Maruf, Scott A. Tomlins, Todd Matthew Morgan, Ganesh S. Palapattu, Eman Adbulfatah, Aaron M. Udager, Simpa Salami
Journal: Journal of Clinical Oncology (2022)

377 Background: Current predictors of metastatic progression after radical nephrectomy for localized clear cell renal cell carcinoma (ccRCC) include clinicopathologic features such as tumor stage and grade. The addition of molecular tumor characteristics in a prognostic score may improve risk stratification and patient selection for enhanced follow up strategies or adjuvant therapies. Methods: We retrospectively identified consecutive patients with ccRCC who underwent radical nephrectomy (RNx) for localized disease. Those who developed metastasis were identified. Whole-transcriptome mRNA sequencing of primary tumors was performed followed by gene set enrichment analysis (GSEA) for the most significant cancer hallmark pathways enriched in patients who did or did not develop metastasis. For each patient, the 22-gene epithelial mesenchymal transition (EMT) score was calculated (high vs. low), using cut-offs from a prior study using TCGA data. The prognostic impact of the EMT score was evaluated by performing multivariable cox-proportional hazard testing and Kaplan-Meier (KM) survival analysis. Results: We analyzed 82 patients with median age 62 years and median tumor size 6 ±2.9 cm. The median time to metastasis after radical nephrectomy for patients who developed metastasis (n = 12) was 18.2 months and 31.1 months for patients who did not develop metastasis (n = 70). We observed a significant enrichment of EMT, myogenesis, inflammatory response and hypoxia hallmark pathways in patients with metastasis vs. those without metastasis. Multivariable analysis controlling for relevant clinicopathologic features such as age, sex, tumor size, tumor stage etc. revealed high EMT score to be significantly associated with development of metastasis [hazard ratio (HR) 7.2; 95% CI 1.15-44.8; ]. Conclusions: Here we validate a prognostic 22-gene epithelial mesenchymal transition (EMT) score in patients treated with radical nephrectomy for localized ccRCC. Pending further studies, the EMT score may improve risk stratification and select patients for adjuvant therapy.
Controversies About Advance Care Planning
Authors: Rebecca L. Sudore, Susan E. Hickman, Anne M. Walling
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First RET Inhibitor on Path to FDA Approval
Journal: Cancer Discovery (2019)

Abstract Investigators in the LIBRETTO-001 phase I/II trial presented new data on the experimental RET inhibitor selpercatinib at the 2019 World Conference on Lung Cancer. The agent produced robust responses in patients with RET-altered non–small cell lung cancer who had already received multiple therapies, raising hopes that it will soon receive FDA approval.
Diabetes-Related Complications and Mortality in Patients With Atrial Fibrillation Receiving Different Oral Anticoagulants
Authors: Huei-Kai Huang, Peter Pin-Sung Liu, Shu-Man Lin, Jin-Yi Hsu, Jih-I Yeh, Edward Chia-Cheng Lai, Carol Chiung-Hui Peng, Kashif M. Munir, Ching-Hui Loh, Yu-Kang Tu
Journal: Annals of Internal Medicine (2022)

Evidence about the association between types of oral anticoagulants and hazards of diabetes complications is limited in patients with atrial fibrillation (AF) and diabetes mellitus (DM).To compare the hazards of diabetes complications and mortality between patients with AF and DM receiving non-vitamin K antagonist oral anticoagulants (NOACs) and those receiving warfarin.A retrospective cohort study.Nationwide data obtained from Taiwan's National Health Insurance Research Database.Patients with AF and DM receiving NOACs or warfarin between 2012 and 2017 in Taiwan were enrolled. Treatment groups were determined by patients' first initiation of oral anticoagulants.Hazards of diabetes complications (macrovascular complications, microvascular complications, and glycemic emergency) and mortality in the NOAC and warfarin users were investigated with a target trial design. Cause-specific Cox proportional hazards models were used to estimate hazard ratios (HRs). Propensity score methods with stabilized inverse probability of treatment weighting were applied to balance potential confounders between treatment groups.In total, 19 909 NOAC users and 10 300 warfarin users were included. Patients receiving NOACs had significantly lower hazards of developing macrovascular complications (HR, 0.84 [95% CI, 0.78 to 0.91]; P < 0.001), microvascular complications (HR, 0.79 [CI, 0.73 to 0.85]; P < 0.001), glycemic emergency (HR, 0.91 [CI, 0.83 to 0.99]; P = 0.043), and mortality (HR, 0.78 [CI, 0.75 to 0.82]; P < 0.001) than those receiving warfarin. Analyses with propensity score matching showed similar results. Several sensitivity analyses further supported the robustness of our findings.The claims-based data did not allow for detailed data on patients' lifestyles and laboratory examinations to be obtained.Non-vitamin K antagonist oral anticoagulants were associated with lower hazards of diabetes complications and mortality than warfarin in patients with AF and DM.Hualien Tzu Chi Hospital.
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction
Authors: Rui Zheng, Ke Zhang, Shanyue Tan, Fang Gao, Yajie Zhang, Wenxia Xu, Huabin Wang, Dongying Gu, Lingjun Zhu, Shuwei Li, Haiyan Chu, Zhengdong Zhang, Lingxiang Liu, Mulong Du, Meilin Wang
Journal: Molecular Cancer (2022)

Abstract Background Exosomes have emerged as vital biomarkers of multiple cancers and contain abundant circular RNAs (circRNAs). However, the potential for exosomal circRNAs to be used in diagnostics and their molecular mechanism of action in colorectal cancer (CRC) remain unclear. Methods CRC-specific exosomal circRNAs were identified by RNA sequencing, exoRBase database and a tissue microarray. The diagnostic performance of plasma exosomal circRNAs was evaluated among cancer-free controls, precancer individuals, CRC patients, and patients with other types of cancer. The corresponding biological functions were mainly assessed using circRNA pull-down, proteomic analysis, and RNA immunoprecipitation assay underlying cellular and mouse models. Results CircLPAR1 was encapsulated in exosomes with high stability and detectability, and its expression in plasma exosomes was remarkably decreased during CRC development but recovered after surgery. Exosomal circLPAR1 showed cancer specificity in CRC diagnosis and increased the diagnostic performance to an area under the receiver operating characteristic curve of 0.875, as determined by analysing its performance in combination with common clinical biomarkers CEA and CA19–9. Additionally, circLPAR1 was downregulated in CRC tissues and was associated with overall survival. Mechanistically, exosomal circLPAR1 was internalized by CRC cells, and it suppressed tumor growth, likely because exosomal circLPAR1 directly bound with eIF3h specifically suppressed the METTL3-eIF3h interaction, decreasing the translation of oncogene BRD4 . Conclusions This comprehensive study highlights plasma exosomal circLPAR1 as a promising predictor in CRC diagnosis and describes its biological regulation of colorectal tumorigenesis. This study provides a new perspective on early diagnosis in the clinic and pathogenesis in disease development.
European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence
Authors: Arjun K. Nambiar, Salvador Arlandis, Kari Bø, Hanny Cobussen-Boekhorst, Elisabetta Costantini, Monica de Heide, Fawzy Farag, Jan Groen, Markos Karavitakis, Marie Carmela Lapitan, Margarida Manso, Serenella Monagas Arteaga, Aisling Nic An Riogh, Eabhann O'Connor, Muhammad Imran Omar, Benoit Peyronnet, Veronique Phé, Vasileios I. Sakalis, Néha Sihra, Lazaros Tzelves, Mary-Lynne van Poelgeest-Pomfret, Tine W.L. van den Bos, Huub van der Vaart, Christopher K. Harding
Journal: European Urology (2022)
SOCIETY NEWS.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Systematic review of safety and efficacy of belimumab in treating immune‐mediated disorders
Authors: Celine Kaegi, Urs C. Steiner, Benjamin Wuest, Catherine Crowley, Onur Boyman
Journal: Allergy (2020)

Abstract Background Biologic agents (also termed biologics or biologicals) are becoming increasingly important in the treatment of immune‐mediated diseases. However, the diversity of clinical trials along with the fast pace of publication makes it difficult to determine the level of evidence for the use of a biologic for a given disorder. To address this challenge, we are publishing a series of systematic reviews evaluating the safety and efficacy of B cell–targeting biologics for the treatment of immune‐mediated diseases. In this article, we have assessed the safety and efficacy of belimumab, a fully human IgG1 monoclonal antibody targeting the cytokine B cell–activating factor (BAFF). Objective To evaluate belimumab's safety and efficacy for the treatment of immune‐mediated disorders compared to placebo, conventional treatment or other biologics. Methods The Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) checklist guided the reporting of the data. We searched the PubMed database between October 4, 2016, and June 23, 2019, concentrating on immune‐mediated disorders. Results The literature search identified 583 articles. After screening titles and abstracts against the inclusion and exclusion criteria and assessing full texts, 17 articles were finally included in a narrative synthesis. Conclusions Belimumab is both safe and effective for the treatment of systemic lupus erythematosus. Results were further promising for the use of belimumab in patients with rheumatoid arthritis and Sjögren’s syndrome. Conversely, results using belimumab in patients with anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis and myasthenia gravis were rather disappointing.
Abstract 364: Association Between Cardiac Arrest to Start of Extracorporeal Cardiopulmonary Resuscitation and Outcome in Patients With Out-of-Hospital Cardiac Arrest Due to Acute Coronary Syndrome
Authors: Shoji Kawakami, Yoshio Tahara, Teruo Noguchi, Shujiro Inoue, Satoshi Yasuda
Journal: Circulation (2018)

Background: The proper timing of introducing extracorporeal cardiopulmonary resuscitation (ECPR) in patients with out-of-hospital cardiac arrest (OHCA) due to acute coronary syndrome (ACS) has yet to be well-established. Hypothesis: The interval of start of ECPR from cardiac arrest is one of predictors of short-term survival in these particularly ill patients. Methods: Between June 2014 and December 2015, we enrolled a total of 13,491 Japanese OHCA patients who were transported to hospitals in a multicenter, prospective fashion (JAAM-OHCA registry). Following exclusion criteria, 72 patients with OHCA due to ACS who were introduced ECPR until return of spontaneous circulation and underwent emergent PCI and target temperature management were eligible for this study (median 59 years-old; 95% male). We investigated the relationship between the interval of start of ECPR or successfully coronary revascularization from cardiac arrest (collapse-to-ECPR or collapse-to-PCI interval) and the survival at 30 days. Results: Patients with survival at 30 days were 50% (n=36). Age, gender, the prevalence of patients with bystander CPR or ST-elevation and collapse-to-PCI interval were comparable between patients with/without survival. The survival patients had the higher prevalence of initial shockable rhythm and the shorter collapse-to-ECPR interval than those without survival (84 vs 57%, p=0.018; 50 vs 57 min, p=0.045). Receiver operating curve analysis indicated collapse-to-ECPR interval cutoff point of 50 min (area under the curve 0.66, sensitivity 54%, specificity 75%) and collapse-to-PCI interval cutoff point of 135 min (0.65, 64%, and 67%, respectively) for predicting survival at 30 days. Multivariate logistic regression analysis revealed initial shockable rhythm and collapse-to-ECPR interval as the independent predictors of survival (OR 5.71, p=0.015; OR 1.05, p=0.025, respectively). Conclusion: Collapse-to-ECPR interval is a significantly associated with 30 days survival in patients with OHCA due to ACS, while collapse-to-PCI interval is not independent predictor of survival in this study. These findings indicate that time management for start of ECPR from cardiac arrest can be essential for improving OHCA patients’ survival.
<i>QuickStats</i>: Death Rates* Attributed to Excessive Cold or Hypothermia,† by Urbanization Level§ and Sex — National Vital Statistics System, 2018–2020
Authors: Merianne Spencer, Matthew Garnett
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

Crude rate of deaths per 100,000 population; 95% CIs indicated by error bars.† Deaths attributed to excessive cold or hypothermia were identified using the International Classification of Diseases, Tenth Revision underlying cause-of-death code X31 (exposure to excessive natural cold) and multiple cause-of-death code T68 (hypothermia).§ Urbanization level is based on county of residence using the National Center for Health Statistics Urban-Rural Classification Scheme for Counties.http://www.cdc.gov/nchs/data/series/sr_02/sr02_166.pdfDuring 2018-2020, death rates attributed to excessive cold or hypothermia were generally higher in more rural areas.Among females, the death rate increased from 0.11 per 100,000 for those residing in large central metro areas, to 0.40 for those in noncore (rural) areas.Among males, the death rates were lowest for those residing in large central metro areas (0.29) and large fringe metro areas (0.24), and highest in noncore (rural) areas (0.93).Males had higher death rates than females for each corresponding urbanization level.
Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact
Authors: Jaydev Dave, Nour Raad, Nishka Mittal, Lu Zhang, Anthony Fargnoli, Jae Gyun Oh, Maria Elisabetta Savoia, Jens Hansen, Marika Fava, Xiaoke Yin, Konstantinos Theofilatos, Delaine Ceholski, Erik Kohlbrenner, Dongtak Jeong, Lauren Wills, Mathieu Nonnenmacher, Kobra Haghighi, Kevin D Costa, Irene C Turnbull, Manuel Mayr, Chen-Leng Cai, Evangelia G Kranias, Fadi G Akar, Roger J Hajjar, Francesca Stillitano
Journal: Cardiovascular Research (2022)

Abstract Aims A mutation in the phospholamban (PLN) gene, leading to deletion of Arg14 (R14del), has been associated with malignant arrhythmias and ventricular dilation. Identifying pre-symptomatic carriers with vulnerable myocardium is crucial because arrhythmia can result in sudden cardiac death, especially in young adults with PLN-R14del mutation. This study aimed at assessing the efficiency and efficacy of in vivo genome editing, using CRISPR/Cas9 and a cardiotropic adeno-associated virus-9 (AAV9), in improving cardiac function in young adult mice expressing the human PLN-R14del. Methods and results Humanized mice were generated expressing human wild-type (hPLN-WT) or mutant (hPLN-R14del) PLN in the heterozygous state, mimicking human carriers. Cardiac magnetic resonance imaging at 12 weeks of age showed bi-ventricular dilation and increased stroke volume in mutant vs. WT mice, with no deficit in ejection fraction or cardiac output. Challenge of ex vivo hearts with isoproterenol and rapid pacing unmasked higher propensity for sustained ventricular tachycardia (VT) in hPLN-R14del relative to hPLN-WT. Specifically, the VT threshold was significantly reduced (20.3 ± 1.2 Hz in hPLN-R14del vs. 25.7 ± 1.3 Hz in WT, P &amp;lt; 0.01) reflecting higher arrhythmia burden. To inactivate the R14del allele, mice were tail-vein-injected with AAV9.CRISPR/Cas9/gRNA or AAV9 empty capsid (controls). CRISPR-Cas9 efficiency was evaluated by droplet digital polymerase chain reaction and NGS-based amplicon sequencing. In vivo gene editing significantly reduced end-diastolic and stroke volumes in hPLN-R14del CRISPR-treated mice compared to controls. Susceptibility to VT was also reduced, as the VT threshold was significantly increased relative to controls (30.9 ± 2.3 Hz vs. 21.3 ± 1.5 Hz; P &amp;lt; 0.01). Conclusions This study is the first to show that disruption of hPLN-R14del allele by AAV9-CRISPR/Cas9 improves cardiac function and reduces VT susceptibility in humanized PLN-R14del mice, offering preclinical evidence for translatable approaches to therapeutically suppress the arrhythmogenic phenotype in human patients with PLN-R14del disease.
Abstract 343: Association Between Hospital Arrival Time and Outcomes in Patients With Out-of-Hospital Cardiac Arrest Due to Acute Myocardial Infarction: JAAM-OHCA Study Group
Authors: Hayato Hosoda, Atsushi Hirayama, Yoshio Tahara, Takahiro Nakashima, Yu Kataoka, Yasuhide Asaumi, Kunihiro Nishimura, Teruo Noguchi, Satoshi Yasuda
Journal: Circulation (2018)

Background: Whether arrival time is associated with in-hospital managements and outcomes in patients out-of-cardiac arrest (OHCA) due to acute myocardial infarction (AMI) is still unclear. Methods: We conducted a multi-institutional, observational study (JAAM-OHCA study) of OHCA from June 2014 through December 2015 in Japan. The primary exposure was hospital arrival time divided into three groups, defining weekday regular time as 8:00 AM to 4:59 PM, weekday night time as 5:00PM to 7:59AM, and weekends/holidays as Saturday, Sunday and holidays. The outcome measures were in-hospital managements (i.e., percutaneous coronary intervention [PCI], intra-aortic balloon pump [IABP], extracorporeal cardiopulmonary resuscitation [ECPR], and target temperature management [TTM]), and neurologically intact survival at 30-day. To determine the associations of hospital arrival time with these outcomes, we constructed logistic regression models adjusting for patient characteristics, out-of-hospital care and in-hospital care, with generalized estimating equations accounting for patient clustering within hospitals. Results: We recruited 13,491 patients with OHCA. Of these, 852 had return of spontaneous circulation and was diagnosed as AMI; n=299 arrived during weekday regular time; n=265 arrived during weekday night time; n=288 arrived during weekends or holidays. Finally, a total of 219 (25.7%) OHCA patients had neurologically intact survival at 30-day. The rates of in-hospital management were not different among the three groups except IABP use (P&lt;0.01). Compared to patients arrived during weekday regular time, neurologically intact survival rate at 30-day was not significantly different in patients arrived during weekday night time and weekends/holiday (26.1% [78 of 299] in weekday regular time group, 22.6% [60 of 265] in weekday night time group, and 28.1% [81 of 288] in weekends/holidays group) with corresponding adjusted odds ratios of 0.80 (95% confidence interval [CI] 0.45-1.40; P=0.43) and 0.96 (95% CI 0.57-1.63; P=0.89). Conclusion: In this observational study of adult patients with OHCA due to AMI, in-hospital managements and outcomes were not differed across hospital arrival time groups.